Business Description
Sana Biotechnology Inc
NAICS : 541714
SIC : 2833
ISIN : US7995661045
Share Class Description:
SANA: Ordinary SharesTotal Employee Number:
142Description
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates comprises SC291, SC262, UP421, and others.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.34 | |||||
Equity-to-Asset | 0.32 | |||||
Debt-to-Equity | 0.63 | |||||
Debt-to-EBITDA | -0.39 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 17.6 | |||||
3-Year EPS without NRI Growth Rate | 22.3 | |||||
3-Year FCF Growth Rate | 29.8 | |||||
3-Year Book Growth Rate | -38.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 12.31 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 85.02 | |||||
9-Day RSI | 74.33 | |||||
14-Day RSI | 66.32 | |||||
3-1 Month Momentum % | 5.25 | |||||
6-1 Month Momentum % | -21.13 | |||||
12-1 Month Momentum % | 13.43 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.29 | |||||
Quick Ratio | 1.29 | |||||
Cash Ratio | 1.17 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -11.8 | |||||
Shareholder Yield % | 1.5 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -149.92 | |||||
ROA % | -59.51 | |||||
ROIC % | -62.8 | |||||
3-Year ROIIC % | -50.58 | |||||
ROC (Joel Greenblatt) % | -253.35 | |||||
ROCE % | -57.67 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 8.09 | |||||
EV-to-EBIT | -4.74 | |||||
EV-to-Forward-EBIT | -5.79 | |||||
EV-to-EBITDA | -5.02 | |||||
EV-to-FCF | -7.22 | |||||
Earnings Yield (Greenblatt) % | -21.1 | |||||
FCF Yield % | -13.49 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SANA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sana Biotechnology Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.93 | ||
| Beta | 3.7498 | ||
| 3-Year Sharpe Ratio | 0.22 | ||
| 3-Year Sortino Ratio | 0.42 | ||
| Volatility % | 81.49 | ||
| 14-Day RSI | 66.32 | ||
| 14-Day ATR ($) | 0.218724 | ||
| 20-Day SMA ($) | 3.0795 | ||
| 12-1 Month Momentum % | 13.43 | ||
| 52-Week Range ($) | 2.61 - 6.55 | ||
| Shares Outstanding (Mil) | 278.29 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sana Biotechnology Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sana Biotechnology Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 127 days | ||
| Second quarter earnings results for 2026 | 2026-08-11 16:05 | In 41 days | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-09 16:00 | 2.69 (-1.82%) | ||
| General meeting for 2026 | 2026-06-04 09:00 | 3.12 (-3.41%) | ||
| Jefferies Global Healthcare Conference | 2026-06-03 09:20 | 3.24 (+2.86%) | ||
| Guidance call for 2026 | 2026-05-12 14:20 | 3.56 (-0.28%) | ||
| First quarter earnings results for 2026 | 2026-05-11 16:05 | 3.51 (+1.74%) | ||
| Sana will present at the Citizens Life Sciences Conference | 2026-03-11 13:40 | 3.29 (-2.66%) | ||
| Annual report for 2025 | 2026-03-03 | 4.15 (+3.75%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-03 | 4.15 (+3.75%) |
Show
Entries
Sana Biotechnology Inc Frequently Asked Questions
What is Sana Biotechnology Inc(SANA)'s stock price today?
The current price of SANA is $3.57. The 52 week high of SANA is $6.55 and 52 week low is $2.61.
When is next earnings date of Sana Biotechnology Inc(SANA)?
The next earnings date of Sana Biotechnology Inc(SANA) is 2026-08-11 Est..
Does Sana Biotechnology Inc(SANA) pay dividends? If so, how much?
Sana Biotechnology Inc(SANA) does not pay dividend.
Guru Commentaries on NAS:SANA
No articles.
Press Release
Articles on Sana Biotechnology Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers